Meeting
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
Authors
Ruchit Shah
Daiichi Sankyo Inc., Basking Ridge, NJ
Ruchit Shah, Furaha Kariburyo-Yay, Jon Apple, Lincy S. Lal, Vincent Miller, Jackie Kwong, Joshua E. Reuss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Real-World Evidence
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 534)
DOI
10.1200/OP.2023.19.11_suppl.534
Abstract #
534
Poster Bd #
L9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2023 ASCO Annual Meeting
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.
First Author: Aurélie Swalduz
Poster
2020 ASCO Quality Care Symposium
Biomarker testing patterns and use of targeted therapy in Medicare Fee-for-Service (FFS) beneficiaries newly diagnosed with metastatic non-small cell lung cancer (mNSCLC).
First Author: Anik Patel